A phase I study of intravenous (emulsion) fenretinide in children with recurrent or resistant neuroblastoma
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Fenretinide (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 22 Dec 2016 Biomarkers information updated
- 26 Apr 2013 Planned end date changed from 1 Apr 2010 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 26 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.